Molly shares the status of two pipeline migraine treatments, Timolol and Qtrypta. She also recaps findings from a study The Headache and Migraine Policy Forum performed on how the pandemic is impacting migraine patients.
The Association of Migraine Disorders recaps their annual Migraine Symposium.
Molly joins us again to recap three news updates you need to know about. Hear about a treatment method now available without a prescription, research on combination therapy and a potential new preventive medication.
Today, Molly is recapping findings from new research by the Cleveland Clinic, the NYU College of Dentistry and Amgen.
Can a person’s sexual orientation impact their risk of migraine? What new medications are on the horizon? Are occipital nerve stimulators an effective treatment for new daily persistent headache with migraine features? Molly O’Brien reports on recent news that will answer these questions.
Molly O’Brien gives an update on research findings by Harvard, a new app from Ctrl M Health and developments by Salvia Bioelectronics.
More than 39 million Americans live with migraine, yet the average medical professional only receives 1 hour of medical training on this disease during medical school. The Association of Migraine Disorders is on a mission to change this with its live, one-day, educational lecture series which will be held virtually at MigraineSymposium.org on October 3, 2020.
See the impact that one of the world’s largest migraine awareness campaigns made.
Shades for Migraine, an international awareness campaign, is asking participants to take their support for people with migraine one step further by signing and sharing a petition urging healthcare payors to provide better access to life-changing migraine treatments by eliminating barriers like step-therapy and high copays.
The Association of Migraine Disorders launches a comprehensive, online, continuing education course on the diagnosis and treatment of migraine.
The years of migraine flying under the radar are behind us. Though there is still much progress to be made, the last few years have been some of the most monumental we’ve seen for the migraine community, making us all the more excited for 2020.
As the year comes to a close, we are recapping the five highest viewed blog posts from 2019… 1. Pregnancy and Migraine Medications Pregnancy is a step into the unknown. It can be the most wonderful time in a person’s life, but it can also be intimidating. For women living with migraine disease, contemplating pregnancy can be downright
Why? A simple and poignant question. It has been a breakthrough for so many. A three-letter word that cuts toward the core of understanding. I have heard both theoretical scientists and three-year-olds use this same question. Each trying to desperately grow their minds by willing it towards understanding the world around them. The day I asked the question of, why, on the side of a Tennessee path I was searching for the answers to why my stomach had revolted abruptly and violently. Leaving an otherwise patch of dry leaves moist and putrefied. The immediate causes I tried to line out but the solution still eludes me today. Even through the leaves and my unavailable powers of divination, I could see that my day was done. The “why?” of being there was easy. I have believed for some time that there is a need to show others the impact of migraine. I use arduous efforts of physical endurance to strike conversations about migraine.
It’s a Bird, It’s a Plane, It’s a Super-Responder: A Story of Life After Aimovig I sat staring at my phone, anxiously hitting the refresh button. The FDA was slated to announce their approval of Amgen’s new migraine prevention drug sometime today and the sun was beginning to set. As darkness began to fall, my heart began to beat faster.
2018 has arguably been one of the most transformative years in migraine, from revolutionary treatments to worldwide awareness. Here’s a recap!
We’ve asked people with migraine what gifts they’d love to receive this holiday, plus the gifts you should avoid at all costs. Here’s what they said.